Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of OMS 824 binding activity to PDE 10 in brains of healthy volunteers.

Trial Profile

Phase I trial of OMS 824 binding activity to PDE 10 in brains of healthy volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs OMS 824 (Primary)
  • Indications Cognition disorders; Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Apr 2014 Early findings will be presented at the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) according to an Omeros Corporation media release.
    • 11 Feb 2014 Since the maximum tolerated dose has not been reached in the latest cohort, Omeros is now planning to evaluate a higher dose of OMS 824 in the trial to determine whether a higher level of PDE10 occupancy can be achieved, according to a media release.
    • 11 Feb 2014 Additional positive results published in an Omeros Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top